Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Zdiagnozowana białaczka limfocytowa lub chłoniak limfocytowy
- •Pacjent wymaga leczenia zgodnie ze standardami medycznymi
- •Brak wcześniejszego systemowego leczenia (za wyjątkiem naświetlań lub krótkotrwałych sterydów)
- •Wiek co najmniej 18 lat
- •Dobry ogólny stan zdrowia (skala ECOG 0-2)
- •Prawidłowe liczby krwinek i funkcja wątroby oraz nerek
- •Dla kobiet w wieku rozrodczym: negatywny test ciąży
- •Dla kobiet w wieku rozrodczym: zgoda na skuteczną antykoncepcję
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 22, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Massachusetts General Hospital
Boston, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Trial contact
Jacob Soumerai, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.